0001209191-21-053710.txt : 20210827
0001209191-21-053710.hdr.sgml : 20210827
20210827183157
ACCESSION NUMBER: 0001209191-21-053710
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210826
FILED AS OF DATE: 20210827
DATE AS OF CHANGE: 20210827
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kalowski Lee
CENTRAL INDEX KEY: 0001618273
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 211220441
MAIL ADDRESS:
STREET 1: C/O TOKAI PHARMACEUTICALS, INC.
STREET 2: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-26
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001618273
Kalowski Lee
C/O BICYCLE THERAPEUTICS PLC
B900, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
0
1
0
0
President and CFO
Ordinary Shares
2021-08-26
4
M
0
550
8.76
A
550
D
Ordinary Shares
2021-08-26
4
S
0
550
35.04
D
0
D
Ordinary Shares
2021-08-27
4
M
0
7950
8.73
A
7950
D
Ordinary Shares
2021-08-27
4
S
0
7950
35.15
D
0
D
Stock Option (Right to Buy)
8.76
2021-08-26
4
M
0
550
0.00
D
2029-03-07
Ordinary Shares
550
13718
D
Stock Option (Right to Buy)
8.73
2021-08-27
4
M
0
7950
0.00
D
2029-03-07
Ordinary Shares
7950
5768
D
Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.374675 to GBP 1.00 as of August 26, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $35.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (5).
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3709 to GBP 1.00 as of August 27, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.08 to $35.18 inclusive.
25% of the shares vested on January 1, 2020, and the remaining vested or shall vest in 36 equal monthly installments.
/s/ Lee Kalowski
2021-08-27